ATLANTA--(BUSINESS WIRE)--Holzer & Holzer, LLC is investigating whether Evolus, Inc. (“Evolus” or the “Company”) (NASDAQ: EOLS) complied with the federal securities laws. On May 16, 2018, Evolus announced that the FDA sent a Complete Response Letter related to the Company’s Biologics License Application for DWP-450, a developmental treatment of frown lines. The FDA’s Complete Response Letter noted deficiencies in Evolus’ Chemistry, Manufacturing and Controls processes. The price of Evolus stock fell following the announcement.
If you purchased Evolus common stock and suffered a loss on that investment, you are encouraged to contact Corey D. Holzer, Esq. at firstname.lastname@example.org or Alexandria P. Rankin, Esq. at email@example.com, or call the firm by toll-free telephone at (888) 508-6832.
Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content.